Ключевые аспекты ценообразования. Международная практика
Tools to Reduce Phase III Trial Failures Lawrence J. Lesko, Ph.D., FCP Director of the Office of Clinical Pharmacology and Biopharmaceutics Center for.
Critical Path: Overview of Selected Ongoing CBER Efforts and Future Opportunities Jesse L. Goodman, M.D., M.P.H Director Center for Biologics Evaluation.
FDA Critical Path Initiative: A Generic Industry Perspective